Arrowhead Is A Buy On REDEMPLO™ Approval And Strong Cash Runway (NASDAQ:ARWR)

Today, we take a look at Arrowhead Pharmaceuticals, Inc. ( ARWR ), who celebrated a transformational milestone on November 18 th with the approval of their lead drug candidate REDEMPLO™ (previously Plozasiran). REDEMPLO™ isI have a background in Risk Management, Finance, and Engineering and I write about what interests me. I hope you find it helpful - comments and questions are welcome.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no pl ...